Syndax Pharmaceuticals Inc (SNDX) stock
SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.56−0.64 (-6.96%)
Close on Nov 18, 2026Market cap $764.38MP/E –Yield –
Syndax Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Syndax Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$178.64M. For fiscal 2025 it was -$273.08M. The highest annual figure on record is $26.22M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$273.08M | – |
| FY2024 | Dec 31, 2024 | -$339.67M | – |
| FY2023 | Dec 31, 2023 | -$229.95M | – |
| FY2022 | Dec 31, 2022 | -$151.76M | -678.8% |
| FY2021 | Dec 31, 2021 | $26.22M | – |
| FY2020 | Dec 31, 2020 | -$71.42M | – |
| FY2019 | Dec 31, 2019 | -$57.54M | – |
| FY2018 | Dec 31, 2018 | -$75.88M | – |
| FY2017 | Dec 31, 2017 | -$61.95M | – |
| FY2016 | Dec 31, 2016 | -$43.77M | – |
| FY2015 | Dec 31, 2015 | -$20.51M | – |
| FY2014 | Dec 31, 2014 | -$21.33M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$41.90M | – |
| Q2 FY2026 | Jun 30, 2026 | -$40.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$34.20M | – |
| Q4 FY2025 | Dec 31, 2025 | -$62.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$57.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$69.35M | – |
| Q1 FY2025 | Mar 31, 2025 | -$83.76M | – |
| Q4 FY2024 | Dec 31, 2024 | -$96.37M | – |
| Q3 FY2024 | Sep 30, 2024 | -$89.58M | – |
| Q2 FY2024 | Jun 30, 2024 | -$74.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$79.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$77.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$56.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$49.68M | – |
| Q1 FY2023 | Mar 31, 2023 | -$46.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$42.03M | -143.9% |
| Q3 FY2022 | Sep 30, 2022 | -$35.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$37.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$36.86M | – |
| Q4 FY2021 | Dec 31, 2021 | $95.75M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.03M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.33M | – |
| Q1 FY2021 | Mar 31, 2021 | -$27.16M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.86M | – |
| Q3 FY2020 | Sep 30, 2020 | -$19.85M | – |
| Q2 FY2020 | Jun 30, 2020 | -$16.61M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.10M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.21M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.15M | – |
| Q2 FY2019 | Jun 30, 2019 | -$15.37M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.81M | – |
| Q4 FY2018 | Dec 31, 2018 | -$19.33M | – |
| Q3 FY2018 | Sep 30, 2018 | -$17.84M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.95M | – |
| Q1 FY2018 | Mar 31, 2018 | -$19.75M | – |
| Q4 FY2017 | Dec 31, 2017 | -$19.49M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.45M | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.84M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.18M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.14M | – |
See a number that looks wrong?